OptimizeRx Corporation (OPRX) Financial Ratios
19 years of historical data (2007–2025) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
↓
6.55
↓-97% vs avg
5yr avg: 224.70
30Y Low13.4·High85.3
P/FCF
↓
6.62
↓-99% vs avg
5yr avg: 1159.30
30Y Low12.5·High185.5
P/B Ratio
↓
0.98
↓-68% vs avg
5yr avg: 3.05
30Y Low0.8·High27.6
ROE
↑
4.2%
↓+160% vs avg
5yr avg: -6.9%
30Y Low-365%·High12%
Debt/EBITDA
↑
0.29
↑+35% vs avg
5yr avg: 0.22
30Y Low0.1·High0.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OPRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
OptimizeRx Corporation trades at 24.6x earnings, 98% below its 5-year average of 1473.9x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 10%. On a free-cash-flow basis, the stock trades at 6.6x P/FCF, 99% below the 5-year average of 1159.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $124M | $233M | $89M | $245M | $299M | $1.1B | $462M | $137M | $130M | $46M | $24M |
| Enterprise Value | $105M | $214M | $109M | $268M | $281M | $1.0B | $452M | $119M | $121M | $41M | $17M |
| P/E Ratio → | 24.56 | 45.41 | — | — | — | 2902.34 | — | — | 574.35 | — | — |
| P/S Ratio | 1.13 | 2.13 | 0.97 | 3.43 | 4.78 | 17.93 | 10.67 | 5.59 | 6.14 | 3.81 | 3.10 |
| P/B Ratio | 0.98 | 1.82 | 0.76 | 1.94 | 2.37 | 8.36 | 9.25 | 3.06 | 7.05 | 7.44 | 3.08 |
| P/FCF | 6.62 | 12.48 | 18.61 | — | 28.70 | 4577.39 | — | — | 185.50 | — | — |
| P/OCF | 6.60 | 12.45 | 18.18 | — | 28.04 | 1513.36 | — | — | 164.20 | — | — |
P/E links to full P/E history page with 30-year chart
OPRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
OptimizeRx Corporation's enterprise value stands at 6.5x EBITDA, 97% below its 5-year average of 224.7x. The Healthcare sector median is 14.4x, placing the stock at a 54% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.96 | 1.18 | 3.75 | 4.50 | 16.55 | 10.43 | 4.85 | 5.72 | 3.39 | 2.20 |
| EV / EBITDA | 6.55 | 13.37 | — | — | — | 436.03 | — | — | 244.09 | — | — |
| EV / EBIT | 8.97 | — | — | — | — | 2809.20 | — | — | 153.87 | — | — |
| EV / FCF | — | 11.48 | 22.76 | — | 26.98 | 4225.97 | — | — | 172.80 | — | — |
OPRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
OptimizeRx Corporation earns an operating margin of 10.7%. Operating margins have expanded from -36.9% to 10.7% over the past 3 years, signaling improving operational efficiency. ROE of 4.2% is modest. ROIC of 7.1% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.3% | 67.3% | 64.5% | 60.0% | 62.4% | 58.1% | 55.7% | 62.8% | 57.6% | 49.1% | 56.0% |
| Operating Margin | 10.7% | 10.7% | -14.9% | -36.9% | -19.7% | 0.6% | -4.9% | -15.0% | 0.8% | -17.6% | -20.4% |
| Net Profit Margin | 4.7% | 4.7% | -21.8% | -24.6% | -18.3% | 0.6% | -5.1% | -12.8% | 1.1% | -17.3% | -19.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.2% | 4.2% | -16.5% | -13.9% | -8.9% | 0.4% | -4.7% | -9.9% | 1.8% | -30.0% | -18.4% |
| ROA | 2.9% | 2.9% | -11.3% | -11.0% | -8.3% | 0.4% | -3.8% | -7.7% | 1.3% | -19.8% | -12.9% |
| ROIC | 7.1% | 7.1% | -7.2% | -15.4% | -11.9% | 0.6% | -4.8% | -15.3% | 2.5% | -170.4% | -156.8% |
| ROCE | 7.6% | 7.6% | -8.6% | -18.1% | -9.5% | 0.4% | -4.2% | -10.4% | 1.3% | -30.4% | -18.9% |
OPRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
OptimizeRx Corporation carries a Debt/EBITDA ratio of 0.3x, which is very conservative (91% below the sector average of 3.3x). The company holds a net cash position — cash of $23M exceeds total debt of $5M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.28 | 0.29 | 0.00 | 0.00 | 0.01 | 0.01 | — | — | — |
| Debt / EBITDA | 0.29 | 0.29 | — | — | — | 0.14 | — | — | — | — | — |
| Net Debt / Equity | — | -0.15 | 0.17 | 0.18 | -0.14 | -0.64 | -0.20 | -0.41 | -0.48 | -0.82 | -0.90 |
| Net Debt / EBITDA | -1.17 | -1.17 | — | — | — | -36.26 | — | — | -17.95 | — | — |
| Debt / FCF | — | -1.00 | 4.15 | — | -1.73 | -351.42 | — | — | -12.71 | — | — |
| Interest Coverage | — | — | -2.23 | -18.16 | — | — | — | — | — | — | — |
Net cash position: cash ($23M) exceeds total debt ($5M)
OPRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
OptimizeRx Corporation's current ratio of 3.04x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.04 | 3.04 | 2.89 | 3.04 | 11.74 | 12.29 | 3.28 | 4.44 | 3.77 | 2.49 | 2.78 |
| Quick Ratio | 3.04 | 3.04 | 2.89 | 3.04 | 11.74 | 12.29 | 3.28 | 4.44 | 3.77 | 2.49 | 2.78 |
| Cash Ratio | 1.10 | 1.10 | 0.72 | 0.77 | 8.83 | 9.04 | 1.05 | 3.09 | 2.11 | 1.45 | 1.92 |
| Asset Turnover | — | 0.62 | 0.54 | 0.39 | 0.46 | 0.43 | 0.72 | 0.43 | 0.85 | 1.24 | 0.68 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 125.92 | 151.39 | 190.30 | 129.49 | 147.69 | 150.72 | 110.07 | 111.15 | 103.26 | 144.11 |
OPRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
OptimizeRx Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 4.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.1% | 2.2% | — | — | — | 0.0% | — | — | 0.2% | — | — |
| FCF Yield | 15.1% | 8.0% | 5.4% | — | 3.5% | 0.0% | — | — | 0.5% | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.0% | 3.1% | 6.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 3.4% |
| Total Shareholder Yield | 0.0% | 0.0% | 1.0% | 3.1% | 6.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 3.4% |
| Shares Outstanding | — | $19M | $18M | $17M | $18M | $18M | $15M | $13M | $12M | $10M | $10M |
Peer Comparison
Compare OPRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OPRXYou | $124M | 24.6 | 6.5 | 6.6 | 67.3% | 10.7% | 4.2% | 7.1% | 0.3 |
 HCAT | $113M | -0.6 | — | — | 48.7% | -51.7% | -58.3% | -32.9% | — |
 DOCS | $5B | 23.5 | 21.1 | 19.6 | 90.2% | 39.9% | 22.5% | 20.0% | 0.1 |
 PRVA | $3B | 133.3 | 57.6 | 18.6 | 9.9% | 1.6% | 3.1% | 9.9% | 0.2 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PGNY | $2B | 29.5 | 16.4 | 8.2 | 23.6% | 6.6% | 12.5% | 18.1% | 0.3 |
 VEEV | $27B | 30.9 | 28.4 | 19.3 | 75.5% | 28.7% | 13.9% | 12.9% | 0.1 |
 MCK | $92B | 29.2 | 18.7 | 17.6 | 3.5% | 1.2% | — | 540.6% | 1.5 |
 TDOC | $1B | -6.1 | 15.1 | 4.4 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 AMWL | $129M | -1.3 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 CERT | $1B | -631.0 | 11.0 | 10.9 | 61.5% | 5.0% | -0.2% | 1.5% | 0.1 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 19 years · Updated daily
See OPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OPRX vs HCAT
Side-by-side business, growth, and profitability comparison vs Health Catalyst, Inc..
Start ComparisonOPRX — Frequently Asked Questions
Quick answers to the most common questions about buying OPRX stock.
What is OptimizeRx Corporation's P/E ratio?
OptimizeRx Corporation's current P/E ratio is 24.6x. The historical average is 45.4x.
What is OptimizeRx Corporation's EV/EBITDA?
OptimizeRx Corporation's current EV/EBITDA is 6.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 49.3x.
What is OptimizeRx Corporation's ROE?
OptimizeRx Corporation's return on equity (ROE) is 4.2%. The historical average is -58.8%.
Is OPRX stock overvalued?
Based on historical data, OptimizeRx Corporation is trading at a P/E of 24.6x. Compare with industry peers and growth rates for a complete picture.
What are OptimizeRx Corporation's profit margins?
OptimizeRx Corporation has 67.3% gross margin and 10.7% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does OptimizeRx Corporation have?
OptimizeRx Corporation's Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.